Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Screenshot of a prostate lesion in mint Lesion

Streamline Prostate Cancer Screenings with Prostate.Carcinoma.ai in mint Lesion

The Prostate.Carcinoma.ai plug-in, developed by our partner FUSE-AI, is a powerful addition to mint Lesion, designed specifically to enhance prostate cancer screenings. This advanced solution leverages artificial intelligence to automate and accelerate prostate MR evaluations based on the PI-RADS 2.1 guidelines, transforming the workflow and precision for radiologists.

At the click of a button, Prostate.Carcinoma.ai performs full segmentation of the prostate and its anatomical zones, and detects and segments potentially malignant lesions. mint Lesion maps each finding onto the standardized prostate lesion scheme, eliminating the need for time-consuming manual lesion annotation and drawing.

Radiologists maintain full control over the AI-generated results, with the ability to review, reject, modify, or add new findings to ensure accuracy. Based on these inputs, mint Lesion automatically calculates the PI-RADS score, delivering a comprehensive and structured report.

mint Lesion also enables longitudinal tracking of prostate lesions for MRI-based active surveillance. Radiologists can easily monitor changes in lesions over time, supporting informed decision-making for patient management and enhancing the continuity of care.

Learn more on our partner page.

Related Resources

Related Resources

AI lung nodules detection in contextflow and Lung-RADS in mint Lesion

Leverage Advanced AI-Driven Nodule Detection and Analysis for Comprehensive Patient Care

Discover the power of streamlined AI-driven lung screening with contextflow ADVANCE Chest CT integrated into mint Lesion. With automated lung nodule…

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing…

Image shows graphic related to study's research on iRECIST and RECIST

University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…